Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis
J Invest Dermatol, 2022.
Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups.
Read publication: J Invest Dermatol
Related
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe pso...
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR
The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celeb...
0 Comments